CurrentBlue Cross Blue Shield - MassachusettsPolicy 328

Pancreas Transplantation Coverage Criteria

Medical necessity and coverage criteria for pancreas transplantation (simultaneous pancreas-kidney, pancreas after kidney, pancreas alone, and retransplantation) for commercial members of Blue Cross Blue Shield of Massachusetts.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyPancreas Transplantation Coverage Criteria

Policy CodePolicy 328

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient pancreas transplantation and follow OPTN and CMS NCD requirements when requesting authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

812pancreas-kidney transplants (2023, US)

102pancreas-alone transplants (2023, US)

22.4%type 2 diabetes share (2022)

3-yr ~94–95%reported 3-yr survival

25,000IPTR cases analyzed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Medically Necessary Indications

Pancreas transplantation is considered medically necessary in specific scenarios when ALL applicable criteria are met for the listed transplant types:

Covered transplant types: Simultaneous pancreas-kidney (SPK) for insulin-dependent diabetic individuals with uremia; pancreas after kidney (PAK) for insulin-dependent diabetic individuals after prior kidney transplant; pancreas alone (PA) for insulin-dependent diabetic individuals with severely disabling and potentially life-threatening complications due to hypoglycemia unawareness and labile diabetes despite optimal medical management; pancreas retransplantation for individuals who meet criteria for pancreas transplantation.

Supported by registry and retrospective data showing improved outcomes (see Summary of Evidence).

PA severity requirements

Additional required severity criteria for pancreas transplant alone (PA):

PA severity: Candidates must meet at least one of: documented severe hypoglycemia unawareness (e.g., chart notes or emergency department visits) OR documented potentially life-threatening labile diabetes (e.g., hospitalization for diabetic ketoacidosis).

Most pancreas transplant recipients have type 1 diabetes; PA is investigational in other situations.

Pancreas transplantation is not covered when any of the following are present: recent malignancy with high risk of recurrence; known current malignancy, including metastatic cancer; other irreversible end-stage disease not attributed to kidney disease; untreated systemic infection (including chronic infection) that makes immunosuppression unsafe; history of cancer with a moderate risk of recurrence; psychosocial conditions or chemical dependency that affect the ability to adhere to lifelong immunosuppression; or systemic disease that could be exacerbated by immunosuppression.

Clinicians should be aware that published evidence has identified pancreas transplant alone (PA) as an independent risk factor for subsequent renal failure in some cohorts; this study finding supports careful assessment of baseline renal function and counseling about potential renal risk when considering PA.

Pancreas transplantation is considered investigational for indications not explicitly described as medically necessary in this policy. For pancreas transplant alone (PA), the policy limits medical necessity to candidates meeting defined severity criteria; all other PA scenarios and any other uses not meeting the stated criteria are investigational.

Candidate Selection and Eligibility

Candidate criteria for pancreas transplantation

General candidate selection and PANCREAS-ALONE additional criteria:

General pancreas transplant candidate: Insulin-dependent diabetes with an appropriate clinical indication (SPK with uremia; PAK after prior kidney transplant; PA for severe hypoglycemia unawareness or life‑threatening labile diabetes), absence of exclusionary conditions (see exclusions), and psychosocial ability to adhere to lifelong immunosuppression. The transplant team must assess malignancy recurrence risk and provide justification for recently treated cancers.

Registry and retrospective evidence support survival benefit in these groups.

PA additional severity requirement: For PA candidates: severe hypoglycemia unawareness OR potentially life‑threatening labile diabetes (eg, hospitalization for diabetic ketoacidosis).

Documentation should be present in chart notes, ED visits, or hospitalization records.

Candidate selection factors

References and studies informing candidate selection considerations (age, HIV status, diabetes type, prior kidney transplant status).

candidate_factors: Clinical factors studied include recipient age, HIV infection, type 1 versus type 2 diabetes, and prior kidney transplant status (simultaneous vs pancreas‑after‑kidney).

These factors are referenced in registry, cohort, and guideline literature informing selection considerations.

Contraindications

Absolute or relative contraindications to pancreas transplantation include: recent malignancy with high risk of recurrence, known current malignancy (including metastatic disease), untreated systemic infection that would make immunosuppression unsafe (including chronic infections), and other irreversible end-stage disease not attributed to kidney disease. Additional contraindications include a history of cancer with moderate risk of recurrence, psychosocial or chemical dependency issues that impair adherence to therapy, and systemic diseases likely to be worsened by immunosuppression.

The policy text does not list HIV infection as an absolute contraindication; instead, management of HIV-infected transplant candidates is addressed in referenced specialty guidance. For candidates with recently treated malignancy, the transplant team must assess recurrence risk and provide documentation explaining why the patient is an appropriate candidate. Centers must also meet applicable certification and policy requirements when documenting eligibility.

Pre-Transplant Evaluation and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization and adherence to policy are required for transplant services. Providers must obtain prior authorization per Blue Cross Blue Shield - Massachusetts procedures and demonstrate that the requested transplant meets policy medical necessity criteria.

Prior authorization required before scheduling transplant-related services
Provide full clinical documentation supporting medical necessity per policy 328

Documentation Required

Evaluation for Prior or Recent Malignancy

The transplant team must assess the risk of malignancy recurrence for any patient with a history of cancer. For recently treated malignancy, the transplant team’s clinical judgment and risk assessment must be documented. Providers must submit a statement explaining why the patient with a recently treated malignancy is an appropriate transplant candidate.

Assessment of recurrence risk performed and documented by transplant team
Provider-submitted justification required when there is a recent or treated malignancy

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Preauthorization required for inpatient procedures

Precertification/preauthorization is required for services described in this policy when the procedure is performed inpatient; outpatient prior authorization requirements depend on product.

CPT/HCPCS/ICD-10 coding and procedure setting affect preauthorization expectations.

Prior Authorization

Follow OPTN policies and CMS NCD when requesting authorization

When seeking authorization, providers should follow applicable OPTN policies and the CMS National Coverage Determination (NCD 260.3) and document compliance with those requirements.

Note

No additional provider action specified

No specific provider action was specified in the referenced chunks.

Documentation Required

Transplant-team statement required for recently treated malignancy

For candidates with a recently treated malignancy, the transplant team must submit a statement explaining why the patient is an appropriate transplant candidate, addressing assessment of recurrence risk.

Statement must explain appropriateness despite recent malignancy and address recurrence risk.

Documentation Required

Document CMS transplant certification and NCD 260.3 compliance

Centers should document compliance with CMS transplant certification expectations and the CMS National Coverage Determination for pancreas transplants (NCD 260.3).

CMS transplant certification resources and NCD 260.3 are referenced in the policy's citations.

Denial Risk

Conditions that trigger noncoverage

Pancreas transplantation is not covered when recent or current high‑risk malignancy, untreated systemic infection, other irreversible end‑stage disease not due to kidney disease, history of cancer with moderate recurrence risk, psychosocial/chemical dependency affecting adherence, or systemic disease that could be worsened by immunosuppression are present.

Denial Risk

OPTN policy noncompliance can result in denial

Noncompliance with Organ Procurement and Transplantation Network (OPTN) policies may lead to denial or non‑coverage if procedural or listing requirements are not met; providers should ensure OPTN policy adherence.

OPTN Policies: Updated 29, 2024 are cited as relevant to center and listing requirements.

Transplant Center and Program Requirements

Note

Plan for lifelong immunosuppression and OPTN/UNOS prioritization

Transplant recipients require lifelong immunosuppression and transplant prioritization is guided by Organ Procurement and Transplantation Network/UNOS severity criteria; centers must plan for long‑term immunosuppression management.

Documentation Required

Adhere to OPTN (2024) and CMS center requirements

Transplant centers are expected to adhere to OPTN requirements (referenced OPTN policies updated 2024) and to CMS certification standards as cited in the policy references.

Documentation Required

OPTN and CMS adherence referenced for center requirements

Policy references reiterate the need for transplant centers to follow OPTN policies (Updated 2024) and CMS certification expectations as part of center operations and documentation.

Post-Transplant Care and Follow-up

Post-transplant immunosuppression and follow-up — key points

RequirementTransplant recipients require life-long immunosuppression to prevent rejection.

Follow-upOngoing post-transplant follow-up is standard of care to monitor graft function and manage immunosuppression.

PrioritizationPatients are prioritized for transplant by mortality risk and severity of illness criteria developed by the Organ Procurement and Transplantation Network/UNOS.

Pancreas retransplantation — evidence and considerations

Evidence sourcesPancreas retransplantation is discussed in TEC assessments and multiple cohort and registry studies (see TEC Assessment; IPTR and other cohort studies).

Outcomes discussedStudies report outcomes after retransplantation, including analyses of graft and patient survival and comparisons with primary transplants.

Clinical implicationRetransplantation may be considered for patients with prior graft failure who meet transplant candidacy criteria; outcomes are variable and informed by cited studies.

Definitions and Scenarios

Pancreas transplant scenarios (definitions)

SPK (Simultaneous pancreas-kidney)Combined pancreas-plus-kidney transplant, typically for insulin-dependent diabetic individuals with uremia.

PAK (Pancreas after kidney)Pancreas transplant performed after a prior kidney transplant to treat insulin-dependent diabetes.

PA (Pancreas alone)Pancreas transplant alone for insulin-dependent diabetes with severe hypoglycemia unawareness or life-threatening labile diabetes despite optimal medical management.

RetransplantationRepeat pancreas transplantation after primary graft failure; considered when patient continues to meet candidacy criteria.

Pancreas retransplantation — definition and referenced outcomes

DefinitionPancreas retransplantation refers to repeat pancreas transplantation after graft failure.

Key referencesDiscussed in TEC Assessment (Pancreas Retransplantation) and multiple cohort studies and registry analyses (e.g., Gasteiger 2018; Fridell 2015; Buron 2013).

Clinical noteRetransplantation outcomes and indications are informed by these assessments and studies; patient selection should follow standard candidacy criteria and consider prior graft and patient factors.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyPancreas Transplantation Coverage Criteria

Policy CodePolicy 328

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient pancreas transplantation and follow OPTN and CMS NCD requirements when requesting authorization.

SourceLink

On This Page

OFYGOZO	Transplantation of Pancreas, Allogeneic, Open Approach
OFSGOZZ
OFSG4ZZ	Reposition Pancreas, Percutaneous Endoscopic Approach

OpenPayer

Pancreas Transplantation Coverage Criteria

Coverage and Medical Necessity Criteria

Candidate Selection and Eligibility

Contraindications

Pre-Transplant Evaluation and Documentation

Provider Requirements, Prior Authorization, and Documentation

Procedure and Diagnosis Codes

Transplant Center and Program Requirements

Post-Transplant Care and Follow-up

Definitions and Scenarios

Background and Evidence Summary